2018, FDA Approval, Protein Expression and Regulations

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2018

FDA Approval

Protein Expression

Regulations

Roche to present new data in multiple sclerosis and neuromyelitis optica spectrum disorder at MSVirtual2020

The Pharma Data

SEPTEMBER 2, 2020

New Phase III data from SAkuraStar and SAkuraSky studies demonstrate reduced severity of relapses with ENSPRYNG (satralizumab), recently FDA-approved as the first and only subcutaneous treatment for adults living with anti-aquaporin-4 (AQP4) antibody positive neuromyelitis optica spectrum disorder (NMOSD).

Clinical Trials

Clinical Trials Disease Treatment Therapies

2021 AAN highlight impact and breadth of expanding neuroscience portfolio

The Pharma Data

APRIL 8, 2021

Food and Drug Administration (FDA) approved EVRYSDI for the treatment of SMA in adults and children 2 months of age and older. EVRYSDI was granted PRIME designation by the European Medicines Agency (EMA) in 2018 and Orphan Drug Designation by FDA and EMA in 2017 and 2019, respectively. Europe and Japan.

Clinical Trials

Clinical Trials Trials Disease Nurses

Drug Discovery Digest

Roche to present new data in multiple sclerosis and neuromyelitis optica spectrum disorder at MSVirtual2020

2021 AAN highlight impact and breadth of expanding neuroscience portfolio

Stay Connected